GET DAILY SIGNALSMedtronic (MDT) Gains +11.9% in 30 Days Following MiniMed Separation
Key Takeaways
- Medtronic (MDT) climbed from a closing price of $86.29 on September 30, 2026 to $96.54 on October 30, 2026, a gain of approximately +11.9% over 30 days.
- The move was driven primarily by the completed separation of its diabetes business, MiniMed Group, whose oversubscribed exchange offer retired roughly 55 million Medtronic shares.
- Strong fiscal 2027 first-quarter results, new reimbursement codes, European regulatory approvals, and constructive analyst actions reinforced the rally.
- Over the trailing quarter, the stock advanced roughly 12% to 13%, building on a broader recovery from its mid-2026 lows.
- Medtronic raised its quarterly dividend again and now stands one increase away from Dividend King status after 49 consecutive years of dividend growth.
- For additional context on valuation, upcoming results, and long-term projections, explore dedicated Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioning around this ticker, explore Trending AI Robots.
Medtronic (MDT) at a Glance: Company Overview
Medtronic plc remains one of the largest medical technology firms globally, with operations spanning cardiovascular, neuroscience, medical surgical, and formerly diabetes-related areas. Its lineup features cardiac rhythm devices, ablation systems, surgical tools, spinal implants, and robotic platforms such as Hugo and Stealth AXiS. Following the spin-off of MiniMed Group, the company now centers on its core cardiovascular, neuroscience, and surgical segments. I follow the stock for its diversified revenue streams, recurring procedure demand, defensive characteristics, and nearly five decades of consistent dividend growth.
MDT Stock Performance: The Last 30 Days and the Broader Quarter
From September 30 to October 30, 2026, MDT moved from a close of $86.29 to $96.54, delivering roughly +11.9%. Volume picked up notably in mid-October around the MiniMed settlement, and the shares continued climbing to close the month at $96.54 after touching an intraday peak above $98. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Looking back across the full quarter, the shares rose about 12.6% from a late-July close near $85.71. The low point around $72.50 in early June 2026 marked the start of a steady recovery that carried the price toward the upper end of its recent range by late October.
Key Drivers Behind the 30-Day Advance
The main catalyst was the final separation of MiniMed Group. The exchange offer was oversubscribed, and the October 15 settlement allowed Medtronic to retire approximately 55 million of its own shares, which should support earnings per share going forward and sharpen focus on higher-margin businesses. Additional tailwinds included new CPT codes effective in 2028 for Altaviva and Symplicity Spyral, CE Mark approval for the Vitalis pacemaker line in Europe, positive registry data on Sphere-9 and PulseSelect presented at APHRS 2026, and recognition of Stealth AXiS and the Corsano wearable on TIME’s 2026 Best Inventions list. Analyst notes stayed generally supportive, with RBC Capital holding a Buy rating and $118 target while BTIG kept a Buy at $99; Piper Sandler and J.P. Morgan maintained Hold views.
Quarterly Context and Longer-Term Recovery
Fiscal 2027 first-quarter results, ended July 31, 2026, showed revenue of about $9.76 billion, up 13.7% year over year, and adjusted EPS of $1.45 that topped estimates near $1.39. Cardiovascular revenue grew roughly 19%, aided by traction in cardiac ablation solutions. Management expects the MiniMed separation to lift operating margins by around 100 basis points. The company also increased its quarterly dividend by 1.4% to $0.72 per share, extending its streak to 49 consecutive years of raises and positioning it one step from Dividend King status. These elements, alongside a defensive healthcare stance in the market, underpinned the multi-month rebound from the mid-2026 low.
What to Watch Next for MDT
The mid-November 2026 earnings release will be the next focal point, with consensus calling for roughly $1.34 in EPS and $9.47 billion in revenue. Investors will track whether organic growth stays near double digits, how the separation influences reported margins, and any updates to full-year guidance. Other items include adoption rates for Affera, Sphere-9, Altaviva, and Symplicity Spyral, progress with Hugo and Stealth AXiS platforms, and competition from peers such as Johnson & Johnson, Abbott Laboratories, and Stryker, plus broader macro and policy trends. These points are for informational purposes only and not investment recommendations.
Exploring AI-Driven Strategies Around MDT
In my own research, I have found Tickeron’s AI Trading Bots useful for monitoring how automated systems interpret momentum and technical signals on names like Medtronic in real time. The platform surfaces a range of strategies that vary by holding period and risk parameters, allowing users to compare approaches across different market environments. I often review the trending section to see which bots are currently generating the strongest signals for a given ticker.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDT in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 43 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 26 of 43 cases over the following month. The odds of a continued upward trend are 60%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 171 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 237 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 16 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MDT broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 25 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.458) is normal, around the industry mean (4.209). P/E Ratio (23.604) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.253). Dividend Yield (0.030) settles around the average of (0.010) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical technology services
Industry MedicalNursingServices
Advertisement